

**STRIDES PHARMA CANADA INC.**  
**BALANCE SHEET AS AT MARCH 31, 2019**

	Amount in CAD	Amount in CAD
	31-Mar-19	31-Mar-18
<b>A ASSETS</b>		
<b>I Non-current assets</b>		
(a) Property, plant and equipment	350	
(b) Financial assets		
(i) Investments	1     3,803,195	-
<b>Total non-current assets</b>	<b>3,803,545</b>	<b>-</b>
<b>I Current assets</b>		
(a) Financial assets		
(i) Trade receivables	2     242,847	
(ii) Cash and cash equivalents	3     43,078	1,000
(iii) Other financial assets	4     151	
(b) Other current assets	5     28,282	
<b>Total current assets</b>	<b>314,359</b>	<b>1,000</b>
<b>TOTAL ASSETS</b>	<b>4,117,903</b>	<b>1,000</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
(a) Equity share capital	6     1,000	1,000
(b) Other equity	7     3,726,157	(22,026)
<b>Total Equity</b>	<b>3,727,157</b>	<b>(21,026)</b>
<b>II Liabilities</b>		
<b>1 Current liabilities</b>		
(a) Financial liabilities		
(i) Trade payables	8     390,746	7,119
(ii) Other financial liabilities	9     -	14,907
<b>Total current liabilities</b>	<b>390,746</b>	<b>22,026</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>4,117,903</b>	<b>1,000</b>

**STRIDES PHARMA CANADA INC.**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2019**

Particulars	Note No.	Amount in CAD	
		31-Mar-19	31-Mar-18
<b>1</b> Revenue from operations	10	242,847	-
<b>2</b> Other Income		-	-
<b>3 Total Revenue (1+2)</b>		<u>242,847</u>	<u>-</u>
<b>4 Expenses</b>			
(a) Purchases of stock in trade		181,980	-
(b ) Employee benefits expense	11	1,932	-
(c) Finance costs	12	317	
(d ) Depreciation and amortisation expense		175	
(e) Other expenses	13	289,843	22,026
<b>Total expenses</b>		<u>474,247</u>	<u>22,026</u>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<u>(231,400)</u>	<u>(22,026)</u>
<b>6</b> Exceptional Item		(243,500)	
<b>7 Profit / (Loss) before taxes (5+6)</b>		<u>(474,900)</u>	<u>(22,026)</u>
<b>8 Tax Expense:</b>			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		<u>-</u>	<u>-</u>
<b>VII Profit / (Loss) for the year after tax</b>		<u>(474,900)</u>	<u>(22,026)</u>

STRIDES PHARMA CANADA INC.  
STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED MARCH 31, 2019

(A) Equity share capital

Particulars	Amount in CAD
<b>Balance as at March 31, 2017</b>	-
Changes in equity share capital during the year	1,000
<b>Balance as at March 31, 2018</b>	<b>1,000</b>
Changes in equity share capital during the year	
<b>Balance as at March 31, 2019</b>	<b>1,000</b>

(B) Other equity

Particulars	Share application money pending allotment	Reserves and surplus		Items of other comprehensive income	Total
		Retained earnings	-	Re -measurement of the defined benefit liabilities / (assets)	
<b>Balance as at March 31, 2017</b>	-	-	-	-	-
Profit/loss for the year		(22,026)			(22,026)
Other comprehensive income for the year (net of tax)					-
<b>Balance as at March 31, 2018</b>	-	(22,026)		-	<b>(22,026)</b>
Application money received during the year	<b>4,223,084</b>				4,223,084
Profit/loss for the year		(474,900)			(474,900)
Other comprehensive income for the year (net of tax)					-
<b>Balance as at March 31, 2019</b>	<b>4,223,084</b>	<b>(496,926)</b>		-	<b>3,726,157</b>

STRIDES PHARMA CANADA INC.  
Notes forming part of financial statement

Note

No.

		Amount in CAD	
		31-Mar-19	31-Mar-18
<b>1</b>	<b>Non current investments</b>		
	<b>Particulars</b>		
	Pharmapar Inc	3,803,195	
	<b>Total</b>	<b>3,803,195</b>	<b>-</b>
<b>2</b>	<b>Trade receivables</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	<b>Unsecured</b>		
	Considered good	242,847	
	Considered doubtful	-	
		242,847	-
	Less: Allowance for doubtful trade receivables	-	
	<b>Total</b>	<b>242,847</b>	<b>-</b>
<b>3</b>	<b>Cash and cash equivalents</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Cash in hand		
	Balances with banks:		
	In current accounts	43,078	1,000
	In deposit accounts		
	<b>Total</b>	<b>43,078</b>	<b>1,000</b>
<b>4</b>	<b>Other financial assets</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Advances to related parties	151	
	Accrued Interest receivables		
	<b>Total</b>	<b>151</b>	<b>-</b>
<b>5</b>	<b>Other current assets</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	<b>Unsecured, considered good</b>		
	Loans and advances to employees		
	Loans and advances to suppliers		
	Loans and advances to Group entities		
	Balances with government authorities:		
	Prepaid Expenses	28,282	
	<b>Total</b>	<b>28,282</b>	<b>-</b>
<b>6</b>	<b>Share capital</b>		
	<b>Particulars</b>	<b>31-Mar-18</b>	<b>31-Mar-18</b>
	<b>Issued, subscribed and fully paid-up</b>		
	Equity share capital	1,000	1,000
	Preference share capital	-	-
	<b>Total</b>	<b>1,000</b>	<b>1,000</b>
<b>7</b>	<b>Reserves and surplus</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Share Application money Pending Allotment	4,223,084	-
		<b>4,223,084</b>	<b>-</b>
	<b>Surplus in statement of profit and loss</b>		
	Opening balance	(22,026)	-
	Add: Profit / (Loss) for the year	(474,900)	(22,026)
	Less: Equity dividend	-	-
	Less: Preference dividend	-	-
	<b>Closing balance</b>	<b>(496,926)</b>	<b>(22,026)</b>
	<b>Total</b>	<b>3,726,157</b>	<b>(22,026)</b>
<b>8</b>	<b>Trade payables</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Trade payable	390,746	7,119
	<b>Total</b>	<b>390,746</b>	<b>7,119</b>
<b>9</b>	<b>Other Current financial Liabilities</b>		
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Payable to group entities	-	14,907
	<b>Total</b>	<b>-</b>	<b>14,907</b>

STRIDES PHARMA CANADA INC.  
Notes forming part of financial statement

Note

No.

<b>10 Revenue from operations</b>		<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Sale of Product	242,847	-
	Sale licensing Income		-
	<b>Total</b>	<b>242,847</b>	<b>-</b>

<b>11 Employee Benefit Expenses</b>		<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Salaries and wages		
	Superannuation Fund		
	Staff Welfare	1,932	
	<b>Total</b>	<b>1,932</b>	<b>-</b>

<b>12 Finance cost</b>		<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Other finance Cost	317	
	<b>Total</b>	<b>317</b>	<b>-</b>

<b>13 Other expenses</b>		<b>Amount in CAD</b>	
	<b>Particulars</b>	<b>31-Mar-19</b>	<b>31-Mar-18</b>
	Rates & Taxes	71,529	
	Printing & Stationery	307	
	Communication expenses	1,308	
	Net loss on foreign currency transactions	676	
	Professional fees	216,023	22,026
	<b>Total</b>	<b>289,843</b>	<b>22,026</b>